TMS as a pharmacodynamic indicator of cortical activity of a novel anti‐epileptic drug, XEN1101

Autor: Isabella Premoli, Pierre G. Rossini, Paul Y. Goldberg, Kristina Posadas, Louise Green, Noah Yogo, Simon Pimstone, Eugenio Abela, Gregory N. Beatch, Mark P. Richardson

Publikováno v: Annals of Clinical and Translational Neurology, Vol 6, Iss 11, Pp 2164-2174 (2019)

Abstract Objective Transcranial magnetic stimulation (TMS) produces characteristic deflections in the EEG signal named TMS‐evoked EEG potentials (TEPs), which can be used to assess drug effects on cortical excitability. TMS can also be used to dete

Externí odkaz: https://doaj.org/article/1392a1ff0aba42a1b9d62614b06be7e9

Cortical oscillations to measure anti-epileptic drug activity in clinical trials

Autor: Lorenzo Rocchi, Mark P. Richardson, Viviana Santoro, Gregory N Beatch, Andrea Biondi, Isabella Premoli, Pierre Rossini

The frequency analysis of electroencephalographic (EEG) activity, either spontaneous or evoked by transcranial magnetic stimulation (TMS-EEG), is a powerful tool to investigate changes in brain activity and excitability following the administration o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2dc2772bd1f6124997468e62d01c8cfa
https://doi.org/10.21203/rs.3.rs-121959/v1

Comparison of the Intrinsic Vasorelaxant and Inotropic Effects of the Antiarrhythmic Agents Vernakalant and Flecainide in Human Isolated Vascular and Cardiac Tissues

Autor: Gilbert W. Gleim, Christopher J. Morabito, Joseph J. Lynch, Gregory N. Beatch, Christopher P. Regan

Publikováno v: Journal of Cardiovascular Pharmacology. 61:226-232

This study explored the intrinsic vasorelaxant and inotropic effects of the mixed potassium and sodium channel blocker atrial antiarrhythmic vernakalant and the class IC antiarrhythmic agent flecainide in human isolated subcutaneous resistance artery

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10adadd23d92658554b07cd609b79a2e
https://doi.org/10.1097/fjc.0b013e31827afd29

Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial

Autor: Garth Dickinson, Steen Juul-Möller, Pugazhendhi Vijayaraman, A. John Camm, John Ip, Christian Torp-Pedersen, D. George Wyse, Egon Toft, Gregory N. Beatch

Publikováno v: Camm, A J, Toft, E, Torp-Pedersen, C, Vijayaraman, P, Juul-Moller, S, Ip, J, Beatch, G N, Dickinson, G & Wyse, D G 2012, ' Efficacy and safety of vernakalant in patients with atrial flutter : a randomized, double-blind, placebo-controlled trial ', Europace, vol. 14, no. 6, pp. 804-809 . https://doi.org/10.1093/europace/eur416

Vernakalant is a novel, relatively atrial-selective antiarrhythmic agent for conversion of atrial fibrillation (AF) to sinus rhythm. This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. This w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f327bc58d32cd53c104f82593a5fc23
https://doi.org/10.1093/europace/eur416

The Mechanism of Atrial Antiarrhythmic Action of RSD1235

Autor: Bertrand Plouvier, Peter M.R. Orth, Gregory N. Beatch, Alan M. Ezrin, Grace Jung, Janet Y.C. Chen, Shunping Lin, David Fedida

Publikováno v: Journal of Cardiovascular Electrophysiology. 16:1227-1238

Introduction RSD1235 is a novel drug recently shown to convert AF rapidly and safely in patients.(1) Its mechanism of action has been investigated in a rat model of ischemic arrhythmia, along with changes in action potential (AP) morphology in isolat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1cb3380f948776d2a8038af4718e617
https://doi.org/10.1111/j.1540-8167.2005.50028.x